secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0002007919-25-000007
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx reports ozekibart Phase 1 CRC data: 40% ORR, median PFS 7.85 months
---------------------------------------------------------------------------

- 1 CR, 3 PR among 10 evaluable patients; median PFS of 7.85 months.
- Durable disease control ≥180 days observed in 46.2% of treated patients.
- Grade ≥3 TEAEs in 30.8% of patients; most AEs mild to moderate.
- Expansion cohort enrolling up to 50 patients, data expected Q3 2025.
- Two PRs occurred in patients who had failed prior FOLFIRI-based therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000007/0002007919-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000007/inhibrx-20250121.htm
  HTML page:      https://secwatch.observer/filing/0002007919-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer